webleads-tracker

EFPIA

EFPIA | Reflections on disclosure at ECC2015

Pharma Compliance Info EFPIA | Reflections on disclosure at ECC2015 EFPIA

As we pack up the stand after four fascinating days at the European Cancer Congress 2015, I have a little time to reflect on some of the conversations we have had on industry’s move to disclose publicly payments to health professionals. The first observation is that despite the first disclosures being scheduled for the second quarter of 2016, there are still many individuals in the medical community and even some in the industry that are not yet aware of this transformational step in the relationship between industry and the health professionals we work with. We had a number of conversations …

Read More »

UK HCPs back transparency over their pharma payments

Pharma Compliance Info UK HCPs back transparency over their pharma payments EFPIA

A poll of healthcare professionals (HCPs) in the UK has found that a majority believe payments made by pharma companies should be made public. The survey of more than 500 doctors, nurses, hospital specialists and pharmacists, commissioned by the Association of the British Pharmaceutical Industry (ABPI), indicated that 87% of respondents felt payments should be transparent. To read the article by Phil Taylor

Read More »

The EFPIA Disclosure Code: What needs to be disclosed?

Pharma Compliance Info The EFPIA Disclosure Code: What needs to be disclosed? EFPIA

Across Europe, by the end of June 2016, EFPIA member companies will disclose payments made to health professionals, such as sponsorship to attend meetings, speaker fees, consultancy and advisory boards. How this data will be disclosed will vary according to country; disclosures could be made on company websites or, where available, on a central platform for disclosure. In each case the type of activities subject to the provisions of the EFPIA disclosure code is the same. The EFPIA Disclosure code requires member companies to document and disclose the transfers of value it makes, directly or indirectly, to healthcare professionals (HCPs) …

Read More »

La publication en France et les projets EFPIA à la loupe

Pharma Compliance Info La publication en France et les projets EFPIA à la loupe EFPIA Loi Bertrand

En juin dernier, Market iT, spécialiste des sciences de la vie, en partenariat avec le Think Tank Loi Bertrand et l’AFAR, l’Association Française des Affaires Réglementaires, a réalisé une enquête sur les conditions dans lesquelles les entreprises ont réalisé la première publication de leurs liens d’intérêts sur le site public unique, ainsi que sur l’état d’avancement de leurs projets EFPIA. Pour lire l’article de BMI SYSTEM

Read More »

Les résultats de l’enquête sur la 1ère Publication sur le site public unique et les Projets EFPIA

Pharma Compliance Info Les résultats de l’enquête sur la 1ère Publication sur le site public unique et les Projets EFPIA EFPIA Loi Bertrand Think Tank LB

Le Think Tank Loi Bertrand a lancé en collaboration avec l’AFAR, l’Association Française des Affaires Réglementaires, une enquête sur les conditions dans lesquelles les entreprises ont réalisé la première publication de leurs liens d’intérêts sur le site public unique, ainsi que sur l’état d’avancement de leurs projets EFPIA. Les résultats de cette enquête ont été présentés lors du congrès PharmaCompliance Paris le 23 juin dernier. Pour consulter et télécharger les résultats de cette enquête

Read More »

Could EFPIA’s new code boost pharma’s reputation?

Pharma Compliance Info Could EFPIA's new code boost pharma's reputation? EFPIA

The “eyes of the world will be upon the industry” from next year as disclosure of payments to doctors in Europe becomes mandatory – and pharma must embrace this change to help improve the poor public perception of this relationship. This is according to David Morrow, head of medical excellence at AstraZeneca UK, who was speaking at a conference earlier this year organised in London by CompliMed Compliance. To read the article by Ben Adams

Read More »
X